ABVC BioPharma announced an update on the Company’s eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study. The study entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder, Part II” is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan. The Phase II part II clinical study continues the Phase II part I clinical study of ABV-1505. “All of the subjects who completed the study showed a positive approach to the study during their participation,” said ABVC BioPharma Chief Executive Officer Uttam Patil, Ph. D. “Following the successful completion of the eight-week long treatment, we expect to hear a positive result in the interim analysis report and hope to continue the study in the next part by enrolling another thirty patients to complete the Phase II study. We expect our clinical trials will continue to demonstrate that plant medicine can have significant therapeutic benefits, often with few – if any – side effects.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABVC:
- ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
- ABVC BioPharma receives U.S. patent for ADHD treatment
- ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
- ABVC BioPharma enters global licensing agreement with AiBtl BioPharma
- ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results